Project Grant R01DA061885
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $465,750 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Virginia Commonwealth University (VCU). The award will fund research to develop novel mu opioid receptor (MOR) modulators to counteract the effects of synthetic opioids, which are fueling the opioid crisis in the United States. Specifically, the project will design, synthesize, and characterize a...
- This federal Project Grant award of $623,650 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is funding research at Oregon Health & Science University to investigate how adolescent social isolation and disruption of thyroid hormone signaling in the basolateral amygdala may contribute to substance use disorder vulnerability. The project aims to elucidate the...
- This Project Grant award of $149,804 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify new genetic regulators that influence opioid signaling pathways. The goal is to expand understanding of the opioid signaling landscape and identify potential genetic targets to tune signaling biases for safer and more effective opioid treatments. The University of Florida is the awardee and will implement a MOR-MAPK...
- This federal Project Grant award of $767,506 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to leverage integrative modeling and AI-based tools to develop safer opioid painkillers. The project focuses on understanding how low-efficacy opioid receptor (MOR) agonists activate MOR-mediated G protein pathways differently from high-efficacy opioid drugs, in order to inform the design of safer opioid therapeutics. The award...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
- This federal Project Grant award of $476,496.00, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at American University investigating the role of opioid signaling in reward-guided decision-making within the rat prefrontal cortex. The project, led by the Principal Investigator, will utilize intra-cortical pharmacology, computational modeling, and video analysis to examine how cortical opioid receptors...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $787,594.00 to the Icahn School of Medicine at Mount Sinai to conduct research on the "Cortical Mechanisms of Opioid Reinforcement." The research aims to better understand the molecular, cellular, and circuit-based mechanisms underlying opioid use disorder (OUD). Specifically, the study will investigate the role of a specialized...
- The National Institute on Drug Abuse (NIDA) awarded a $569,743 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University on July 15, 2025. The grant, titled "Y-SCORCH 2.0: Further Data Mining and Functional Characterization for Single Cell Opioid Responses in the Context of HIV (SCORCH) Program," aims to leverage advanced tools to analyze transcriptomic and epigenetic data from the SCORCH consortium and novel spatial transcriptomic data to...
- This federal Project Grant award of $613,786.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to elucidate the molecular, cellular, and physiological consequences of D1 dopamine receptor (D1DR) signaling from both the plasma membrane and Golgi compartments in primary medium spiny neurons. The research aims to advance understanding of the role of compartmentalized D1DR signaling in the neurobiology...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....
This federal Project Grant award of $453,062.00 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to better understand the cellular mechanisms regulating opioid receptor signaling and the development of pharmacological tolerance, which is a critical challenge in the clinical management of opioid-based pain treatments. The research aims to leverage proteomic and genomic approaches to identify key protein networks that regulate trafficking of the mu opioid receptor at the endosomal level, with the goal of developing strategies to enhance receptor recycling and mitigate receptor downregulation as a driver of opioid tolerance. The award was granted to Oregon Health & Science University, a prominent academic medical center, and has a project period from September 1, 2025 to May 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $453.1k | 8/25/25 |